Latest Breaking News On - Genitourinary cancers symposium - Page 12 : vimarsana.com

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence

Results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer .

Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence

21.06.2022 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the results from the Phase 3 PROpel trial have been published in NEJM Evidence. Results from the trial showed that LYNPARZA in combination .

ASCO Reading Room | Carlos Riveros, MD, on Impact of Fragmented Care on Muscle-Invasive Bladder Care

In muscle-invasive bladder cancer (MIBC), the with neoadjuvant chemotherapy followed by radical cystectomy is often delivered at a single facility that provides integrated care. In some cases, however, care can be more , with chemotherapy delivered at one facility and surgery at another.

Advancing Bladder Cancer Treatment by Studying Biomarkers' Ability to Respond to Chemotherapy